898
Participants
Start Date
November 11, 2019
Primary Completion Date
April 15, 2022
Study Completion Date
August 30, 2022
Intermittent Preventive Therapy with Dihydroartemisinin-Piperaquine
Monthly DP fixed dose of 3 tablets (40 mg of dihydroartemisinin and 320 mg of piperaquine) daily for three days until delivery. All participants will (continue to) receive daily cotrimoxazole (CTX) (one double-strength tablet of 160mg of sulfamethoxazole and 800mg of trimethoprim) and anti-retroviral drugs.
Kenya Medical Research Institute, Kisumu
Collaborators (2)
Kenya Medical Research Institute
OTHER
Kamuzu University of Health Sciences
OTHER
Kenya National AIDS & STI Control Programme
OTHER
KEMRI-Wellcome Trust Collaborative Research Program
OTHER
Centers for Disease Control and Prevention
FED
University of Copenhagen
OTHER
University of Cape Town
OTHER
University of Massachusetts, Worcester
OTHER
University of Toronto
OTHER
University of Melbourne
OTHER
CardiaBase
OTHER
Liverpool School of Tropical Medicine
OTHER